Transplacental digoxin therapy for treatment of fetal supraventricular tachycardia
1 Department of Obstetrics and Gynecology, Nnamdi Azikiwe University, Nnewi Campus, PMB 5025, Nnewi, Anambra State, Nigeria.
2 Department of Obstetrics and Gynecology, Nnamdi Azikiwe University Teaching Hospital Nnewi, PMB 5025, Nnewi, Anambra State, Nigeria.
3 Department of Radiology, Nnamdi Azikiwe University, Nnewi Campus, PMB 5025, Nnewi, Anambra State, Nigeria.
Case Study
Magna Scientia Advanced Research and Reviews, 2023, 07(01), 098–102
Article DOI: 10.30574/msarr.2023.7.1.0029
Publication history:
Received on 08 January 2023; revised on 15 February 2023; accepted on 18 February 2023
Abstract:
Fetal supraventricular tachycardia (SVT) is the most common form of primary fetal tachycardia. It is a known cause of non-immune hydrops and can lead to significant perinatal morbidity and mortality. We report a case of a 27-year-old primigravida with a diagnosis of fetal supraventricular tachycardia. Her fetus was treated transplacentally with maternal oral digoxin leading to reversion to sinus rhythm. She was delivered by caesarean section and baby had an uneventful neonatal period.
Keywords:
Arrhythmia; Tachycardia; Supraventricular tachycardia; Digoxin; Hydrops; Hydrops fetalis
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0